At Rafael Pharmaceuticals, Inc. we are a pioneering, clinical-stage, metabolic oncology therapeutics company, focused on transforming the lives of patients with hard to treat cancers. Our primary objective is to produce highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues.

At Rafael Pharmaceuticals, Inc. we are a pioneering, clinical-stage, metabolic oncology therapeutics company, focused on transforming the lives of patients with hard to treat cancers. Our primary objective is to produce highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues.

 

CPI-613

Rafael Pharmaceutical’s first-in-class clinical lead compound, CPI-613, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies as a single agent, as well as in combination with standard drug therapies, in patients diagnosed with advanced solid tumors or blood cancers. The U.S. Food and Drug Administration (FDA) has given Cornerstone approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613 an orphan drug for the treatment of pancreatic cancer, AML, and myelodysplastic syndromes (MDS).

Learn More

World Class Team

Innovation in oncology drug development requires a deep well of scientific, medical and business expertise, and we have assembled an unparalleled team of directors and advisors who will work with Cornerstone to revolutionize anticancer treatment.

Our Board of Directors and Scientific & Medical Advisory Boards are drawn from the highest echelons of oncology and hematology researchers and physicians, and include seasoned managers from the biotech and pharmaceutical sectors.

  • Placeholder

    Chi Van Dang, M.D., Ph.D., Chairman of Rafael’s Scientific and Medical Advisory Boards

    Director of the Abramson Cancer Center of the University of Pennsylvania. Dr. Dang is considered by many to be the world’s leading authority on cancer metabolism. Dr. Dang currently serves as Rafael’s Chairman of the Scientific and Medical Advisory Boards.

  • Placeholder

    Greg Semenza, M.D., Ph.D., Scientific Advisor

    Director, Vascular Program, Institute for Cell Engineering; Professor of Pediatrics, Radiation Oncology and Molecular Radiation Sciences, Biological Chemistry, Medicine, and Oncology at the Johns Hopkins University School of Medicine. Dr. Semenza won the 2016 Lasker Award.

  • Placeholder

    Dafna Bar-Sagi, Ph.D., Scientific Advisor

    Senior Vice President, Vice Dean for Science, Chief Scientific Officer, Professor, Departments of Biochemistry and Molecular Pharmacology, and Medicine, NYU Langone Medical Center

  • Placeholder

    Philip A. Philip, M.D., Ph.D., FRCP, Pancreatic Cancer Advisor

    Professor of Oncology and Pharmacology, Leader, GI and Neuroendocrine Oncology, Vice President of Medical Affairs, Karmanos Cancer Center, Wayne State University, Detroit, MI.

  • Placeholder

    Jorge Cortes, M.D., Acute Myeloid Leukemia Advisor

    Deputy Chair and Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center

  • Placeholder

    Steven I. Park, M.D., Lymphoma Advisor

    Division Chief, Hematology and Oncology, Levine Cancer Institute, CHS-Northeast; Director of Investigational Therapeutics in Hematologic Malignancies, Levine Cancer Institute/Carolinas HealthCare System; Associate Professor of Medicine, University of North Carolina, Chapel Hill

World Class Team

Innovation in oncology drug development requires a deep well of scientific, medical and business expertise, and we have assembled an unparalleled team of directors and advisors who will work with Cornerstone to revolutionize anticancer treatment.

Our Board of Directors and Scientific & Medical Advisory Boards are drawn from the highest echelons of oncology and hematology researchers and physicians, and include seasoned managers from the biotech and pharmaceutical sectors.

  • Placeholder

    Chi Van Dang, M.D., Ph.D., Chairman of Rafael’s Scientific and Medical Advisory Boards

    Director of the Abramson Cancer Center of the University of Pennsylvania. Dr. Dang is considered by many to be the world’s leading authority on cancer metabolism. Dr. Dang currently serves as Rafael’s Chairman of the Scientific and Medical Advisory Boards.

  • Placeholder

    Greg Semenza, M.D., Ph.D., Scientific Advisor

    Director, Vascular Program, Institute for Cell Engineering; Professor of Pediatrics, Radiation Oncology and Molecular Radiation Sciences, Biological Chemistry, Medicine, and Oncology at the Johns Hopkins University School of Medicine. Dr. Semenza won the 2016 Lasker Award.

  • Placeholder

    Dafna Bar-Sagi, Ph.D., Scientific Advisor

    Senior Vice President, Vice Dean for Science, Chief Scientific Officer, Professor, Departments of Biochemistry and Molecular Pharmacology, and Medicine, NYU Langone Medical Center

  • Placeholder

    Philip A. Philip, M.D., Ph.D., FRCP, Pancreatic Cancer Advisor

    Professor of Oncology and Pharmacology, Leader, GI and Neuroendocrine Oncology, Vice President of Medical Affairs, Karmanos Cancer Center, Wayne State University, Detroit, MI.

  • Placeholder

    Jorge Cortes, M.D., Acute Myeloid Leukemia Advisor

    Deputy Chair and Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center

  • Placeholder

    Steven I. Park, M.D., Lymphoma Advisor

    Division Chief, Hematology and Oncology, Levine Cancer Institute, CHS-Northeast; Director of Investigational Therapeutics in Hematologic Malignancies, Levine Cancer Institute/Carolinas HealthCare System; Associate Professor of Medicine, University of North Carolina, Chapel Hill

News & Events

June 05, 2017

Cornerstone Pharmaceuticals, Inc. Announces Corporate Name Change to Rafael Pharmaceuticals, Inc.

Read More

May 09, 2017

The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer

Read More

March 23, 2017

FDA Provides Cornerstone Pharmaceuticals Approval to Initiate Pivotal Study for CPI-613, its Metabolism-Directed Anticancer Compound

Read More

February 8, 2017

Cornerstone Pharmaceuticals, Inc. Announces the Addition of World-Renowned Experts to Scientific and Medical Advisory Boards

Read More

January 10, 2017

Cornerstone Pharmaceuticals, Inc. Announces Additions to its Board of Directors: Jean-Pierre Sommadossi, Ph.D., Richard Axel, M.D., Chi Van Dang, M.D., Ph.D., and Richard Scheller, Ph.D.

Read More

December 5, 2016

Cornerstone Pharmaceuticals, Inc. Presents Phase I Data on CPI-613 in Acute Myeloid Leukemia (AML) and T-Cell Non-Hodgkin’s Lymphoma (T-cell NHL) at ASH 2016

Read More